JP2019527200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527200A5 JP2019527200A5 JP2018566552A JP2018566552A JP2019527200A5 JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5 JP 2018566552 A JP2018566552 A JP 2018566552A JP 2018566552 A JP2018566552 A JP 2018566552A JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- scil
- monomer subunit
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 239000000178 monomer Substances 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000003704 aspartic acid Nutrition 0.000 claims 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 3
- 102220512227 Endosomal/lysosomal potassium channel TMEM175_D41N_mutation Human genes 0.000 claims 2
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims 2
- 101710146672 Interleukin-10 receptor subunit alpha Proteins 0.000 claims 2
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims 2
- 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 108010063954 Mucins Proteins 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 101001133091 Homo sapiens Mucin-20 Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 102100034242 Mucin-20 Human genes 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353478P | 2016-06-22 | 2016-06-22 | |
| US62/353,478 | 2016-06-22 | ||
| PCT/US2017/038747 WO2018005226A2 (en) | 2016-06-22 | 2017-06-22 | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527200A JP2019527200A (ja) | 2019-09-26 |
| JP2019527200A5 true JP2019527200A5 (enExample) | 2020-07-30 |
| JP7084881B2 JP7084881B2 (ja) | 2022-06-15 |
Family
ID=60674961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566552A Active JP7084881B2 (ja) | 2016-06-22 | 2017-06-22 | Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10335459B2 (enExample) |
| EP (1) | EP3474884A4 (enExample) |
| JP (1) | JP7084881B2 (enExample) |
| AU (2) | AU2017291321B2 (enExample) |
| CA (1) | CA3026393C (enExample) |
| WO (1) | WO2018005226A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015171965A2 (en) | 2014-05-07 | 2015-11-12 | Applied Molecular Transport Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| US9090691B2 (en) | 2010-09-15 | 2015-07-28 | Applied Molecular Transport Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US20160175458A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| EP3474884A4 (en) | 2016-06-22 | 2020-08-19 | Alkermes, Inc. | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10 |
| KR20210005602A (ko) * | 2018-03-23 | 2021-01-14 | 가비쉬-가릴리 바이오 어플리케이션스 리미티드. | 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg |
| KR20210110294A (ko) | 2018-11-07 | 2021-09-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 통과세포외배출용 전달 구조체 및 관련 방법 |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
| SI4065585T1 (sl) | 2019-11-25 | 2025-11-28 | Alkermes, Inc. | Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja |
| US20230103554A1 (en) * | 2020-04-03 | 2023-04-06 | Baylor College Of Medicine | TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY |
| MX2022014239A (es) * | 2020-05-12 | 2023-02-09 | Regeneron Pharma | Nuevos agonistas de il10 y metodos para su uso. |
| WO2021243057A1 (en) * | 2020-05-28 | 2021-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered interleukin-10 polypeptides and uses thereof |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| EP4612165A1 (en) * | 2022-11-02 | 2025-09-10 | Synerkine Pharma B.V. | Engineered immunocytokines, fusion polypeptides, and il10 polypeptides |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| WO2024144336A1 (ko) * | 2022-12-30 | 2024-07-04 | 주식회사 프로젠 | 신규 이중 특이성 융합단백질 및 그의 용도 |
| TW202502807A (zh) * | 2023-06-02 | 2025-01-16 | 美商新舍凱公司 | 融合il10多肽 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| JP2002530066A (ja) | 1998-11-19 | 2002-09-17 | スミスクライン・ビーチャム・コーポレイション | Ｒｈａｍｍアンタゴニスト抗体 |
| US6428985B1 (en) * | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| WO2004044006A1 (en) * | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| WO2008140595A2 (en) | 2006-12-01 | 2008-11-20 | President And Fellows Of Harvard College | Synthetic trivalent haptens, complexes thereof, and uses therefor |
| AU2010334974A1 (en) | 2009-12-22 | 2012-07-12 | Novartis Ag | Tetravalent CD47-antibody constant region fusion protein for use in therapy |
| EP2519544A1 (en) * | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| AU2011226992B2 (en) | 2010-05-10 | 2012-03-22 | Ascend Biopharmaceuticals Pty Ltd | Immunostimulatory and vaccine compositions |
| CN101962413B (zh) | 2010-09-21 | 2013-03-13 | 中国科学技术大学 | 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用 |
| KR101333958B1 (ko) | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| EP2457579A1 (en) * | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| PT2748201T (pt) | 2011-08-23 | 2018-02-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas que ativam as células t |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| WO2013184938A2 (en) * | 2012-06-08 | 2013-12-12 | Alkermes. Inc. | Fusion polypeptides comprising mucin-domain polypeptide linkers |
| AU2013293092A1 (en) | 2012-07-23 | 2015-02-26 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| MA20150232A1 (fr) * | 2012-08-08 | 2015-07-31 | Roche Glycart Ag | Protéines de fusion de l'interleukine-10 et leurs utilisations |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| AU2014257123A1 (en) | 2013-04-24 | 2015-10-15 | Armo Biosciences, Inc. | Interleukin-10 compositions and uses thereof |
| KR20250152665A (ko) | 2013-07-31 | 2025-10-23 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| EP3102594A1 (en) | 2014-02-06 | 2016-12-14 | F. Hoffmann-La Roche AG | Interleukine 10 immunoconjugates |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| US20160175458A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EP3474884A4 (en) | 2016-06-22 | 2020-08-19 | Alkermes, Inc. | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10 |
-
2017
- 2017-06-22 EP EP17820960.7A patent/EP3474884A4/en not_active Withdrawn
- 2017-06-22 AU AU2017291321A patent/AU2017291321B2/en not_active Ceased
- 2017-06-22 US US15/630,341 patent/US10335459B2/en active Active
- 2017-06-22 WO PCT/US2017/038747 patent/WO2018005226A2/en not_active Ceased
- 2017-06-22 CA CA3026393A patent/CA3026393C/en active Active
- 2017-06-22 JP JP2018566552A patent/JP7084881B2/ja active Active
-
2019
- 2019-05-16 US US16/414,223 patent/US11534480B2/en active Active
-
2020
- 2020-07-03 AU AU2020204457A patent/AU2020204457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527200A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| JP2009524429A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| JP2018510622A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| JP2013520426A5 (enExample) | ||
| JP2010519252A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2019033754A5 (enExample) | ||
| JP2019122392A5 (enExample) | ||
| JP2014224126A5 (enExample) | ||
| HRP20240640T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| JP2015212284A5 (enExample) | ||
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| JP2014510518A5 (enExample) | ||
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| JP2019163253A5 (enExample) | ||
| JP2019522465A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2017536098A5 (enExample) | ||
| JP2014509851A5 (enExample) | ||
| JP2018504911A5 (enExample) | ||
| JP2014525439A5 (enExample) |